Full Product Name
CYLD siRNA (Human)
Product Synonym Names
CYLD1; KIAA0849; Ubiquitin carboxyl-terminal hydrolase CYLD; Deubiquitinating enzyme CYLD; Ubiquitin thioesterase CYLD; Ubiquitin-specific-processing protease CYLD
Product Gene Name
CYLD sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9NQC7
Specificity
CYLD siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human CYLD gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of CYLD sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
CYLD sirna
siRNA to inhibit CYLD expression using RNA interference
Applications Tested/Suitable for CYLD sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for CYLD. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001035814.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001042355.1
[Other Products]
UniProt Primary Accession #
Q9NQC7
[Other Products]
UniProt Secondary Accession #
O94934; Q7L3N6; Q96EH0; Q9NZX9[Other Products]
UniProt Related Accession #
Q9NQC7[Other Products]
Molecular Weight
107,044 Da
NCBI Official Full Name
ubiquitin carboxyl-terminal hydrolase CYLD isoform 2
NCBI Official Synonym Full Names
cylindromatosis (turban tumor syndrome)
NCBI Official Symbol
CYLD [Similar Products]
NCBI Official Synonym Symbols
EAC; MFT; SBS; TEM; BRSS; CDMT; MFT1; CYLD1; CYLDI; USPL2
[Similar Products]
NCBI Protein Information
ubiquitin carboxyl-terminal hydrolase CYLD
UniProt Protein Name
Ubiquitin carboxyl-terminal hydrolase CYLD
UniProt Synonym Protein Names
Deubiquitinating enzyme CYLD; Ubiquitin thioesterase CYLD; Ubiquitin-specific-processing protease CYLD
Protein Family
Ubiquitin carboxyl-terminal hydrolase
UniProt Gene Name
CYLD [Similar Products]
UniProt Synonym Gene Names
CYLD1; KIAA0849 [Similar Products]
UniProt Entry Name
CYLD_HUMAN
NCBI Summary for CYLD
This gene is encodes a cytoplasmic protein with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains that functions as a deubiquitinating enzyme. Mutations in this gene have been associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
UniProt Comments for CYLD
CYLD: Protease that specifically cleaves 'Lys-63'-linked polyubiquitin chains. Has endodeubiquitinase activity. Plays an important role in the regulation of pathways leading to NF-kappa-B activation. Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation. Negative regulator of Wnt signaling. Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules. Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis. Required for normal cell cycle progress and normal cytokinesis. Inhibits nuclear translocation of NF-kappa-B. Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation. Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells. Negatively regulates TNFRSF11A signaling and osteoclastogenesis. Interacts (via CAP-Gly domain) with IKBKG/NEMO (via proline-rich C-terminal region). Interacts with TRAF2 and TRIP. Interacts with PLK1, DVL1, DVL3, MAVS, TBK1, IKKE and DDX58. Interacts (via CAP-Gly domain) with microtubules. Interacts with HDAC6 and BCL3. Interacts with SQSTM1 and MAP3K7. Identified in a complex with TRAF6 and SQSTM1. Detected in fetal brain, testis, and skeletal muscle, and at a lower level in ***** brain, leukocytes, liver, heart, kidney, spleen, ovary and lung. Isoform 2 is found in all tissues except kidney. Inhibited by phosphorylation at serine residues. Belongs to the peptidase C67 family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Ubiquitin conjugating system; EC 3.4.19.12; Protease; Ubiquitin-specific protease; Tumor suppressor
Chromosomal Location of Human Ortholog: 16q12.1
Cellular Component: nucleoplasm; centrosome; extrinsic to internal side of plasma membrane; cytoplasmic microtubule; perinuclear region of cytoplasm; spindle; midbody; cytosol
Molecular Function: protein binding; structural constituent of ribosome; zinc ion binding; ubiquitin-specific protease activity; protein kinase binding
Biological Process: ubiquitin-dependent protein catabolic process; Wnt receptor signaling pathway; inhibition of NF-kappaB transcription factor; regulation of mitotic cell cycle; innate immune response; negative regulation of NF-kappaB import into nucleus; cell cycle; negative regulation of interferon type I production; negative regulation of T cell differentiation
Disease: Brooke-spiegler Syndrome; Cylindromatosis, Familial; Trichoepithelioma, Multiple Familial, 1
Research Articles on CYLD
1. A) in the 9th exon of the CYLD gene was detected in some mother-daughter patients with multiple trichoepitheliomas.">A heterozygous missense mutation (c.1112C>A) in the 9th exon of the CYLD gene was detected in some mother-daughter patients with multiple trichoepitheliomas.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
